collection
MENU ▼
Read by QxMD icon Read
search

Bipolar depressive disorder

shared collection
9 papers 0 to 25 followers
By Faye Kehler Family Physician and GP Anesthetist since 1987 interested in all aspects of Medicine
https://www.readbyqxmd.com/read/26861447/bipolar-vs-borderline-diagnosis-is-prognosis-once-again
#1
EDITORIAL
S N Ghaemi
No abstract text is available yet for this article.
March 2016: Acta Psychiatrica Scandinavica
https://www.readbyqxmd.com/read/26926124/a-new-option-for-treating-bipolar-i-depression
#2
EDITORIAL
Holly A Swartz, Joseph T Tasosa
No abstract text is available yet for this article.
March 1, 2016: American Journal of Psychiatry
https://www.readbyqxmd.com/read/26628905/the-neurocognitive-functioning-in-bipolar-disorder-a-systematic-review-of-data
#3
Eirini Tsitsipa, Konstantinos N Fountoulakis
BACKGROUND: During the last decades, there have been many different opinions concerning the neurocognitive function in Bipolar disorder (BD). The aim of the current study was to perform a systematic review of the literature and to synthesize the data in a comprehensive picture of the neurocognitive dysfunction in BD. METHODS: Papers were located with searches in PubMed/MEDLINE, through June 1st 2015. The review followed a modified version of the recommendations of the Preferred Items for Reporting of Systematic Reviews and Meta-Analyses statement...
2015: Annals of General Psychiatry
https://www.readbyqxmd.com/read/25851411/distinguishing-bipolar-from-unipolar-depression-the-importance-of-clinical-symptoms-and-illness-features
#4
A K Leonpacher, D Liebers, M Pirooznia, D Jancic, D F MacKinnon, F M Mondimore, B Schweizer, J B Potash, P P Zandi, F S Goes
BACKGROUND: Distinguishing bipolar disorder (BP) from major depressive disorder (MDD) has important relevance for prognosis and treatment. Prior studies have identified clinical features that differ between these two diseases but have been limited by heterogeneity and lack of replication. We sought to identify depression-related features that distinguish BP from MDD in large samples with replication. METHOD: Using a large, opportunistically ascertained collection of subjects with BP and MDD we selected 34 depression-related clinical features to test across the diagnostic categories in an initial discovery dataset consisting of 1228 subjects (386 BPI, 158 BPII and 684 MDD)...
August 2015: Psychological Medicine
https://www.readbyqxmd.com/read/24246116/clinical-assessment-of-lurasidone-benefit-and-risk-in-the-treatment-of-bipolar-i-depression-using-number-needed-to-treat-number-needed-to-harm-and-likelihood-to-be-helped-or-harmed
#5
REVIEW
Leslie Citrome, Terence A Ketter, Josephine Cucchiaro, Antony Loebel
BACKGROUND: Prior to recent FDA approval of lurasidone for treatment of bipolar depression there were only two approved treatments for this condition (quetiapine and olanzapine-fluoxetine combination), and these were as likely to provide therapeutic benefit as adverse effects. We assessed the efficacy, safety, and tolerability of lurasidone for major depressive episodes associated with bipolar I disorder, using number needed to treat (NNT, for benefits), number needed to harm (NNH, for harms), and likelihood of being helped or harmed (LHH, ratio of NNH to NNT, for trade-offs between benefits vs...
February 2014: Journal of Affective Disorders
https://www.readbyqxmd.com/read/24170221/lurasidone-as-adjunctive-therapy-with-lithium-or-valproate-for-the-treatment-of-bipolar-i-depression-a-randomized-double-blind-placebo-controlled-study
#6
RANDOMIZED CONTROLLED TRIAL
Antony Loebel, Josephine Cucchiaro, Robert Silva, Hans Kroger, Kaushik Sarma, Jane Xu, Joseph R Calabrese
OBJECTIVE Few studies have been reported that support the efficacy of adjunctive therapy for patients with bipolar I depression who have had an insufficient response to monotherapy with mood-stabilizing agents. The authors investigated the efficacy of lurasidone, a novel antipsychotic agent, as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression. METHOD Patients were randomly assigned to receive 6 weeks of double-blind adjunctive treatment with lurasidone (N=183) or placebo (N=165), added to therapeutic levels of either lithium or valproate...
February 2014: American Journal of Psychiatry
https://www.readbyqxmd.com/read/24170180/lurasidone-monotherapy-in-the-treatment-of-bipolar-i-depression-a-randomized-double-blind-placebo-controlled-study
#7
RANDOMIZED CONTROLLED TRIAL
Antony Loebel, Josephine Cucchiaro, Robert Silva, Hans Kroger, Jay Hsu, Kaushik Sarma, Gary Sachs
OBJECTIVE: The authors evaluated the efficacy and safety of lurasidone in the treatment of patients with major depressive episodes associated with bipolar I disorder. METHOD: Patients were randomly assigned to receive double-blind treatment with lurasidone (20-60 mg/day [N=166] or 80-120 mg/day [N=169]) or placebo (N=170) for 6 weeks. Primary and key secondary endpoints were change from baseline to week 6 on the Montgomery-Åsberg Depression Rating Scale (MADRS) and depression severity score on the Clinical Global Impressions scale for use in bipolar illness (CGI-BP), respectively...
February 2014: American Journal of Psychiatry
https://www.readbyqxmd.com/read/23583011/effectiveness-of-lurasidone-vs-quetiapine-xr-for-relapse-prevention-in-schizophrenia-a-12-month-double-blind-noninferiority-study
#8
RANDOMIZED CONTROLLED TRIAL
Antony Loebel, Josephine Cucchiaro, Jane Xu, Kaushik Sarma, Andrei Pikalov, John M Kane
OBJECTIVE: To evaluate the relapse prevention efficacy of lurasidone compared with quetiapine XR (QXR) in adults patients with schizophrenia. METHOD: This double-blind study evaluated the relapse prevention efficacy of 12 months of flexible-dose treatment with lurasidone (40-160 mg/day) compared with QXR (200-800 mg/day), in outpatients with an acute exacerbation of chronic schizophrenia who had recently completed a 6-week placebo-controlled trial of treatment with either lurasidone or QXR...
June 2013: Schizophrenia Research
https://www.readbyqxmd.com/read/23480132/the-world-federation-of-societies-of-biological-psychiatry-wfsbp-guidelines-for-the-biological-treatment-of-bipolar-disorders-update-2012-on-the-long-term-treatment-of-bipolar-disorder
#9
Heinz Grunze, Eduard Vieta, Guy M Goodwin, Charles Bowden, Rasmus W Licht, Hans-Jürgen Möller, Siegfried Kasper
OBJECTIVES: These guidelines are based on a first edition that was published in 2004, and have been edited and updated with the available scientific evidence up to October 2012. Their purpose is to supply a systematic overview of all scientific evidence pertaining to the long-term treatment of bipolar disorder in adults. METHODS: Material used for these guidelines are based on a systematic literature search using various data bases. Their scientific rigor was categorised into six levels of evidence (A-F) and different grades of recommendation to ensure practicability were assigned...
April 2013: World Journal of Biological Psychiatry
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"